Top Markets
Coin of the day
BriaCell Therapeutics Corp. BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp.

BCTX
Rank in Stocks #18288
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages... BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.
Share Price
$4.32
Market Cap
$8.14M
Change (1 day)
-6.49%
Change (1 year)
-2.88%
Country
CA
Trade BriaCell Therapeutics Corp. (BCTX)

Category

P/B ratio for BriaCell Therapeutics Corp. (BCTX)
P/B ratio as of 2026 TTM: 0
According to BriaCell Therapeutics Corp. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for BriaCell Therapeutics Corp. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
5.6367 -
DK
6.0433 -
US
2.4872 -
US
4.7311 -
BE
6.9706 -
NL